July 23–24, 2026: Six peptides got a yes vote
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended adding six peptide-related bulk substances to the Section 503A Bulks List:
Emideltide, also called DSIP, did not receive a favorable recommendation.
What the vote means
- The committee reviewed whether these ingredients should be eligible for patient-specific compounding by state-licensed pharmacies.
- The recommendations covered narrow proposed uses—not every recovery or wellness claim made online.
- The votes were advisory. They were not drug approvals and did not change current access rules.
- Products labeled “research use only” remain outside the licensed route for medicine.
What happens next
The final decision belongs to the FDA. As of July 27, 2026, the agency had not announced a decision or deadline. Formal action generally proceeds through a proposed rule, public comment, and a final rule.
A separate peptide committee meeting is expected before the end of February 2027 and will cover different substances. It is not the next step in deciding the status of these six.
Review the official FDA meeting materials.
April 22, 2026: Nominations moved off the active Category 2 table
The FDA moved a group of peptide-related substances off its active Section 503A Category 2 table after their nominations were withdrawn. The group included BPC-157, KPV, TB-500, injectable GHK-Cu, ipamorelin acetate, AOD-9604, PEG-MGF, Melanotan II, and thymosin-alpha 1.
What changed—and what did not
- The substances moved to a separate “nominated but withdrawn” table.
- The change did not add them to the Section 503A Bulks List or authorize compounding.
- The FDA continues to publish its safety concerns, including limited human data and peptide-quality risks.